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ABSTRACT
Frailty is associated with functional decline and reduced ability to cope with physiological challenges. The 
pathophysiological changes in frailty include inflammation, endocrine disturbances, neuromuscular and immune 
dysfunction. However, comprehensive information on the relationship between biological markers and frailty is scarce. 
We aimed to determine the relationship between selected biomarkers and frailty among Malaysian older adults. In this 
cross sectional study, 600 community dwelling older adults were randomly selected from ten different areas in Klang 
Valley. A total of 382 participants met the inclusion criteria and consented to the study. Out of these, a subsamples of 91 
participants were selected for biomarkers analysis. Frailty was defined using Fried’s criteria. Fasting blood glucose, 
lipid profile, albumin, selected frailty biomarkers including IL-6, TNF- alpha and IGF-1 and vitamin D together with free 
L-carnitine and acetyl L-carnitine were analysed. The results showed a significantly higher level of serum IL-6 and TNF-α 
among participants classified as frail as compared to pre-frail and robust (p<0.05). With respect to nutritional biomarkers, 
binary logistic regression showed that vitamin D deficiency is associated with three times higher risk of frailty (p<0.05). 
There was no significant relationship between blood L-carnitines and frailty. Further research is required to explore 
the relationship between L-carnitine and frailty using different parameters involved in L-carnitine homeostasis such as 
CPTII enzyme and OCTN2 mutation. In conclusion, frailty was associated with increased level of inflammatory markers 
and vitamin D deficiency. It is empirical to promote healthy lifestyle or disease management to reduce inflammation and 
increase vitamin D status as one of the frailty prevention action plan among older adults. 
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ABSTRAK
Keuzuran adalah berkaitan dengan kemerosotan status kefungisan dan keupayaan dalam menangani cabaran fisiologi. 
Perubahan patofisiologi keuzuran termasuklah ketakfungsian ototneuro, ketakupayaan fungsi imun, inflamasi dan 
gangguan endokrin. Namun begitu, tidak banyak penyelidikan yang mengkaji hubungan antara petunjuk biologi dan 
keuzuran secara menyeluruh. Oleh itu, kajian ini menentukan hubungan antara petunjuk biologi tertentu dan status 
keuzuran dalam kalangan warga emas. Seramai 600 orang warga emas daripada komuniti dipilih secara rawak dari 
10 buah kawasan di Lembah Klang. Seramai 382 peserta memenuhi kriteria kajian dan bersetuju mengambil bahagian. 
Seramai 91 subjek dipilih daripada sampel keseluruhan untuk analisis petunjuk biologi. Keuzuran didefinasikan daripada 
kriteria Fried. Petunjuk biokimia keuzuran yang dikaji termasuk IL-6, TNF- alfa dan IGF-1 serta vitamin D, bersama-
sama dengan L-karnitin bebas dan asetil L-karnitin dianalisis. Keputusan menunjukkan aras plasma darah IL-6 dan 
TNF-α adalah lebih tinggi secara signifikan dalam kumpulan uzur berbanding, prauzur dan robus (p<0.05). Berhubung 
dengan petunjuk biologi pemakanan, analisis logistik binari menunjukkan kekurangan vitamin D berkaitan dengan 
risiko keuzuran sebanyak tiga kali ganda (p<0.05). Tiada hubungan signifikan antara L-karnitin dalam plasma darah 
dengan keuzuran, oleh itu, penyelidikan lanjut diperlukan untuk mengkaji hubungan antara homeostasis L-karnitin 
seperti enzim CPTII dengan mutasi OCTN2. Kesimpulannya, keuzuran dikaitkan dengan peningkatan tahap penanda 
inflamasi dan kekurangan vitamin D. Terdapat keperluan untuk meningkatkan strategi promosi gaya hidup sihat atau 
pengurusan penyakit untuk menurunkan tahap keradangan dan meningkatkan aras vitamin D bagi mencegah keuzuran 
dalam kalangan warga emas. 
Kata kunci: Keuzuran; L-karnitin; pengantara inflamasi; petunjuk biologi; vitamin D 
INTRODUCTION
Frailty is a distinct clinical syndrome with a biological 
basis (Lang et al. 2010). It is defined as loss of ability to 
adapt to stress as a result of diminished functional reserves 
(Weiss 2011) and declined ability to maintain homeostasis 
(Byard 2015). The pathogenesis of frailty involves 
numerous physiological adaptive response that include 
inflammation, neuromuscular dysfunction, endocrine 
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dysregulation, immune dysfunction, abnormalities in 
energy metabolism (Crenstil 2010) and central nervous 
system failure (Mocchegiani et al. 2010). 
 Screening for frailty among older adults in clinical 
practice is limited probably due to the time consuming 
methods of doing so using standard validated tools 
(Annweiler et al. 2011). It has been suggested that the 
identification of blood markers that distinguish at-risk 
frail older adults would be useful for the purpose of both 
prevention and etiological studies (Collerton et al. 2012). 
In addition, evidence suggested that physiological changes 
are obvious in preclinical stage of frailty (prefrailty). It 
is hypothesized that these alterations are responsible for 
the characteristics that are used to classify the syndrome 
(Shamsi et al. 2012).
 Understanding the mechanisms of aging and 
age-related disorders helps in comprehending frailty 
pathophysiology mechanism (Chung et al. 2009). 
The available evidence strongly suggests that the 
interactions between inflammatory pathway, endocrine 
regulation, mitochondria function, nutrition and genes 
are very important in molecular and physiological 
changes that contribute to the development of frailty in 
older adults (Mocchegiani et al. 2010). Based on the 
suggested mechanisms and etiology of frailty and related 
pathophysiological changes, several biological markers 
have been proposed as frailty biomarkers (Kumar et al. 
2014). 
 The relationship between inflammatory mediators and 
oxidative stress with frailty, mainly Interleukin-6 (IL-6), 
tumor necrosis factor- α (TNF-α), C- reactive protein (CRP), 
homocysteine and oxidative stress has been examined (Lai 
et al. 2014). Significant relationships were reported with 
higher level of IL-6 (Almeida et al. 2012; Collerton et al. 
2012; Lai et al. 2014), whilst the relationships with higher 
level of CRP and TNF-α were controversial. Other frailty 
biomarkers that have been studied are anabolic hormone 
IGF-1 (Leng et al. 2009); immune function (Collerton et 
al. 2012); micronutrients mainly vitamin D (Chang et 
al. 2010; Vogt et al. 2015); vitamin E (Ble et al. 2006); 
presence of heavy metal toxicity (García-Esquinas et al. 
2015); visceral protein (Collerton et al. 2012; Hubbard 
& Woodhouse 2010); multisystem function kidney, 
liver function and lipid profile (Fernández-Garrido et al. 
2014); and telomere length (Telomeres are repetitive DNA 
sequences at the ends of the chromosomes that protect 
the DNA against degradation and maintain chromosomal 
stability) (Saum et al. 2014). Yet, there is no gold standard 
biomarker for frailty that can be used to predict and prevent 
frailty, or used in etiological studies (Annweiler et al. 
2011).
 L-carnitine is a non-essential nutrient, fundamental to 
cellular energy metabolism, synthesized in the liver, kidney 
and brain through the conversion of two essential amino 
acids, lysine and methionine (Crentsil 2010). L-carnitine 
deficiency is associated with persistent inflammatory 
state and immune dysregulation in or for some diseases 
(Campos et al. 1995). Crenstil (2010) has proposed a 
relationship between L-carnitine deficiency and frailty 
through several mechanisms including its effect on skeletal 
muscle metabolism, hyperinflammation, energy production 
and immune cells function. L-carnitine plays an obligatory 
role in mitochondrial function in oxidation of long-chain 
fatty acids. Serum fatty acid was found to be higher with 
increasing age, and the ratio of omega 3 to omega 6 fatty 
acid was significantly lower in older adults (Hall & Jewell 
2012). This might explain the mild proinflammatory state 
often found in older adults (Hall & Jewell 2012). 
 In addition, L-carnitine deficiency may lead to 
frailty through mitochondria dysfunction manifested by 
weakness, sarcopenia and fatigue which are components 
of frailty. Another important point is that muscle weakness 
is a major characteristic of frailty. L-carnitine deficiency 
can affect skeletal muscle function by its role in beta 
oxidation, the main energy source for skeletal muscle 
(Crentsil 2010). High serum L-carnitine levels were also 
found to be correlated with better functional abilities 
(Brass 2001). However, L-cranitine serum level has not 
been extensively studied among frail or prefrail compared 
to robust older adults. We aimed to determine the status of 
suggested frailty biomarkers such as IL-6, TNF- α IGF-1 and 
vitamin D among the three groups of older adults (frail, 
prefrail and robust), and to examine the plasma level of 
L-carnitine as a potential biomarker for frailty. 
MATERIALS AND METHODS
This study is a part of larger cross sectional study conducted 
in Klang Valley, Malaysia as reported earlier in Shahar et 
al. (2015). Ethical approval was obtained from Universiti 
Kebangsaan Malaysia Medical Research and Ethics 
Committee (UKM 1.5.5.5/244/NN-149-2013). Participants 
were selected by multistage random sampling from nine 
rural and urban districts, of which the percentage of older 
adults was 10% and above. More than 600 Malaysian older 
adults aged 60 years and above, were personally invited 
to participate in this study. A total of 574 respondents 
agreed to join the study and signed the consent form. The 
response rate was 92.5%. A total of 382 participants met 
the inclusion criteria and consented to provide their blood 
for biochemical analysis. Out of this figure, a sub samples 
of 91 participants were selected from the; frail, prefrail 
and robust groups. All of the respondents from the frail 
group were included, and the selected prefrail and robust 
groups were then matched for age, gender, educational 
level, economic status and ethnicity. 
 Frailty was defined using Fried’s criteria which is 
widely used in clinical research and for frailty assessment 
(Rockwood et al. 2007). It was developed in a very large 
prospective study (Fried et al. 2001) involving 5000 elderly 
individuals, aiming to develop and validate a phenotype 
of frailty in older adults. Shrinking, exhaustion, weakness, 
slowness and low physical activity were concluded as the 
assessment criteria. Participants with three or more (≥3) 
criteria were defined as frail; with one or two (1 or 2) as 
prefrail; and with zero (0) as robust (Fried et al. 2001).
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 In order to obtain accurate and standard biochemical 
tests, the respondents were asked to fast overnight. 
Peripheral venous blood samples from the respondents 
were collected by a trained phlebotomist. A total of 20 
mL blood was collected in tubes and kept in an ice box 
until it was transferred to the lab. Albumin, fasting blood 
sugars (FBS), glycosylated hemoglobin (HBA1c) and lipid 
profile were conducted at the Path Lab-Pathology and 
Clinical Laboratory, Sdn Bhd - Klang Valley branches - 
Malaysia, for quick analysis. The remaining blood, serum 
and plasma were aliquoted at the Path Lab, then transferred 
and stored in freezer at (-80°C) located at the food analysis 
Lab- Faculty of Health Sciences-UKM, for further analysis. 
Selected frailty biomarkers including IL-6, TNF-α and IGF-1 
in addition to vitamin D were analyzed to determine their 
relationship with frailty. IL-6, TNF-α, IGF-1 and vitamin 
D were detected using the blood serum, while the free, 
total and the acetyl L-carnitine were analyzed using blood 
plasma. 
 The plasma level of L-carnitine and total L-carnitine 
were done using a validated method (Prieto et al. 2006). It 
is an easy and accurate method to measure the L-carnitine 
status in human plasma using spectrophotometric analysis. 
The chemicals were purchased from two companies: 
MERCK SDN BHD and Sigma SDN BHD. The chemicals from 
MERCK were L-carnitine for synthesis, Acetylcoenzyme 
A, Trillium salt, (70-72%) Perchloric acid, Potassium 
Hydroxide pellets for analysis, Hydrochloric acid, and 
Sodium Carbonate anhydrous for analysis. Disodium 
EDTA, 5,5′- dithio-bis (2-Nitrobenzoic acid) DTNB and 
4-(2-hydroxyethyl) -1-piperazineethanesulfonic acid 
HEPES; while Carnitine acetyle transferase chemical was 
bought from Sigma. The steps of the analysis were done 
following Prieto et al. (2006) protocol. The L-carnitine 
insufficiency was defined by the value of free L-carnitine: 
acetyl L-carnitine ratio less than 0.4 as suggested by 
Calabrese et al. (2006). The detection of IL-6, TNF-α, IGF-1 
and vitamin D in the serum was done using Enzyme-linked 
Immunosorbent Assays kit (R&D systems, USA). The 
samples and reagents preparation and assay procedures 
were done following the kits manual provided by the 
company. Vitamin D deficiency was defined by value of 
25(OH)D serum level (<25 nmol/l) (Vogt et al. 2015).
 All statistical analyses were performed using the 
Statistical Package for Social Sciences (SPSS) software, 
version 21.0. An alpha level of (0.05) was considered for 
all the statistical tests in the study. Two sided p values of 
(0.05) and (80%) power were considered to be statistically 
significant. Normality test showed that the data was not 
normally distributed. The mean differences between the 
three groups (frail, prefrail and robust) were tested using 
Kruskal Wallis test as the data was not normally distributed. 
For categorical variables, Chi square test was employed 
to determine the association between frailty status and the 
categorical variables (Vitamin D and L-carnitine deficiency). 
Binary logistic regression was done to determine frailty 
predictors. The multicollinearity, outliers and goodness of 
fit tests was employed to assess how well the model fit the 
data (Field 2013).
RESULTS AND DISCUSSION
The results showed that participants mean age was 68±5.9 
years and there were no significant differences between 
the three groups in term of gender, age, race and economic 
status as shown in Table 1. 
 The mean of albumin, fasting blood sugars and lipid 
profiles were not statistically different between the three 
groups (frail, prefrail and robust), as shown in Table 2. 
 Regarding frailty biomarkers, some of the selected 
frailty biomarkers differed statistically between the three 
groups. The mean inflammatory mediators (IL-6 and TNF-α) 
were higher in frail as compared to prefrail and robust 
group (p<0.05 for all parameters). Similar trend was found 
in IGF-1 but the differences did not reach a significant level. 
Vitamin D deficiency was higher in frail (85%), followed 
by prefrail (76.6%) and robust (54.5%) group (p<0.05). 
L-carnitines plasma level showed no significant differences 
among the three groups and L- Carnitine insufficiency was 
detected in 21.1% frail, 19.8% prefrail and 20.1% robust 
group, with no significant difference between the three 
groups (p>0.05) as shown in Table 3.
TABLE 1. Sociodemographic characteristics (Present as n (%))
Factors N Robust 
(n=30)
Prefrail
(n=32) 
Frail 
(n=29)
P value 
Gender Men
women 
43
48
14(33)
16(33.3)
16 (37)
16(33.3)
13 (30)
16(33.3)
0.678 
Age 60-70
>70 
49
42
17 (35)
13 (31)
19(39)
13(31)
13(26)
16 (38)
0.245
Ethnicity Malay and Indian 
Chinese 
40
51
12 (30)
18 (35)
16(40)
16 (31)
12(30)
17 (34)
0.517
Marital status Married 
Other
53
38
18 (34)
12 (32)
21(40)
11(29)
14 (26)
15(39)
0.18
Monthly income Low <1500 rm 
Moderate- high >1500 rm
35
56
11(31)
19 (34)
13 (38)
19 (34)
11(31)
18(32)
0.079
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 Results from binary logistic regression indicated that 
vitamin D deficiency increased risk of frailty by three 
times, after adjustment for age and gender (OR 3.69, 95% 
CI, p<0.01), and higher level of Interleukin -6 increase the 
risk of frailty (OR 1.2, 95%, p<0.05), as shown in Table 4.
 Blood indicators, such as albumin, lipid profile, fasting 
blood glucose and vitamin D, were assessed in the light of 
their relationship with frailty. Albumin was used in clinical 
setting to predict mortality in elderly and better health and 
nutritional status (Schalk et al. 2004) and associated with 
better functional performance in older adults (Villareal et 
al. 2004). However, in the current study, albumin blood 
level did not show significant relationship with frailty. The 
non-significant results might be due to normal albumin 
blood level in all of study subjects.
 Similar to albumin, there were no significant 
differences in the means of the lipid profile and fasting 
blood glucose between the frail group and the others. 
However, there was a significant association between the 
lower level of high density lipoproteins (HDL) with being 
frail/prefrail; low blood level of HDL associated with double 
risk to develop frailty. Villareal et al. (2004) did not find 
any significant difference in the means of any of the lipid 
profile tests between frail and non-frail elderly. Fried 
et al (2001) reported an association between frailty and 
cardiovascular diseases. This highlights the importance 
for conducting more research to identify the relationship 
between frailty and other chronic diseases and their impact 
on elderly health. 
 Vitamin D, as a frailty biomarker and nutritional 
status parameter, was found to be lower in frail and prefrail 
subjects as compared to robust. This is also reported by 
other researchers (Chang et al 2010; Puts et al. 2005; 
Vogt et al. 2015). Vitamin D has a primary physiological 
role in human body. It is involved in many metabolic 
processes and pathways (Mithal et al. 2009). In elderly, it 
was found that vitamin D status could predict the decline 
in the physical performance (Wicherts et al. 2007); and 
it was related to falls risk, fracture rate and rate of bone 
loss among the elderly (Dawson-Hughes et al. 2005). 
Frailty definition includes physical function impairment 
and metabolic changes. Similarly, vitamin D deficiency 
also leads to physical function impairment and metabolic 
changes (Vogt et al. 2015). 
 Frailty biomarkers reported in the literature including 
the inflammatory mediators (IL-6 and TNF-α) and 
the anabolic hormone (IGF-1) were determined and 
investigated in association with frailty. These biomarkers 
TABLE 3. Frailty biomarkers and L-carnitine blood level, according to frailty status                                                     
and gender (presented in Mean±SD)
Tests  Unit Normal 
range
Robust 
(n=30)
Prefrail 
(n=32)
Frail (n=29) P value 
Interleukin-6 (Il-6) pg/mL 5.4±2.2 6.2±2.8 10.6±5.4 0.000**
Tumor necrosis factor – alpha TNF-α pg/mL 4.6±1.4 6.2±1.8 7.3±6.0 0.017*
Insuline like growth factor (IGF-1) ng/mL (47-190) 62.1±16.5 51.3±13.1 50.7±19.7 0.212
Vitamin D ng/mL >25 23.4±7.7 17.3±4.6 16.2±7.5 0.035*
Free Carnitine μmol/L 33.3±2.1 32.1±9.2 33.6±2.9 0.197
Acetyl Carnitine μmol/L 7.4±4.2 6.2±5.4 7.1±5.3 0.383
Total Carnitine μmol/L 40.6±4.0 39.2±4.6 40.7±3.9 0.651
Free carnitine: Acetyl carnitine 0.226±0.13 0.281±0.36 0.22±0.18 0.585
*significant at p<0.05 using Kruskal Wallis test.
Abbreviations: IL-6: interleukin 6, TNF-α: tumor necrosis factor – alpha, IGF-1: Insuline like growth factor
TABLE 2. Biochemical profile according to frailty status and gender             
(presented as Mean±SD)
Tests Unit Total (91)
Robust
(n=30)
Prefrail
 (n=32)
Frail 
(n=29)
FBG
Total cholesterol 
HDL
LDL 
Triglyceride
TC: HDL
Albumin 
mmol/L
mmol/L
mmol/L
mmol/L
mmol/L
---
g/L
6.00±1.6
5.2±1.1
1.5±0.3
3.2±0.9
1.3±0.7
3.8±1.0
42.7±3.0
6.4±2.5
5.2±1.1
1.4±0.4
3.1±0.9
1.5±0.8
3.9±1.2
42.8±3.1
5.6±0.71
5.1±0.9
1.4±0.6
2.9±0.8
1.3±0.6
3.5±0.9
42.7±2.8
NS: no significant differences using Kruskal Wallis test.
Abbreviation: FBG: fasting blood glucose, HDL= high density lipoprotein, LDL=low density lipoprotein
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were analyzed in a sub-sample from the total participants. 
The results showed a significantly higher serum level of 
IL-6 and TNF- α in frail subjects as compared to prefrail 
and robust. The level of the anabolic hormone IGF-1 
was lower in frail compared to prefrail and robust, but 
it did not reach the significant level. Serum level of the 
inflammatory cytokines IL-6 was correlated with changes 
in body composition, disability and morbidity related to 
aging (Walston et al. 2005). In many other studies higher 
levels of IL-6 and other proinflammatory cytokines were 
reported in frail compared to robust and prefrail (Collerton 
et al. 2012; Hubbard & Woodhouse 2010; Walston et al. 
2005) community dwelling older adults. Collerton et al. 
(2012) reported that IL-6 was a significant predictor of 
frailty status among the very old older adults aged 85 
years and above. Similar findings were reported among 
institutionalized older adults in long term care facilities 
(Lai et al. 2014). All of these findings support the hyper 
inflammation theory of pathophysiological changes in 
frailty. Tumor necrosis factor – alpha (TNF-α), is another 
pro inflammatory cytokines, that usually increases with 
normal aging (de Gonzalo-Calvo et al. 2010), and in age 
related diseases like Alzheimer (Cheng et al. 2014). TNF- α 
has been studied in the light of its relationship with frailty, 
but the results were not consistent as in IL-6. Our study 
results also showed a significant higher serum level of the 
TNF-α in frail compared to prefrail and robust. This was 
contradictory to the reports in other studies that did not 
find a significant association between frailty and TNF-α 
(Collerton et al. 2012; Hubbard & Woodhouse 2010; Lai 
et al. 2014). 
 Changes in the hormones and hormone response in 
aging are documented and correlated with age related 
diseases (Ferrari & Magri 2008; Marzetti et al. 2013). 
Decline in anabolic hormones such as growth hormone and 
insulin like growth factor (IGF-1) is also documented. This 
decline was associated with sarcopenia, cognitive decline 
and other disorders (Jones & Boelaert 2015). Even though 
this study did not find a significant difference in the level 
of IGF-1 among frail, prefrail and robust groups, there was 
a trend for its decline with frailty. Leng et al. (2009) found 
a significant association between frailty and low level of 
IGF-1 in older women with moderate to severe disability. 
Moreover, in a recent study conducted among outpatients’ 
older men, a significant relationship with frailty was found 
(Mohammed & Khater 2015). The differences between the 
results of our study and previous studies is probably due to 
the difference in participants’ selection, analysis methods 
and sample size.
 The relationship between L-carnitine and frailty 
was proposed from the similarities between L-carnitine 
deficiency and pathophysiological changes that occurred 
in frailty, namely abnormalities in energy metabolism, 
inflammation and impaired in immune function (Crentsil 
2010). L-carnitine supplementation improved muscle 
function (Rivero et al. 2002), decreased fatigue (Cavallini 
et al. 2004; Malaguarnera et al. 2007), improved body 
composition and regulated inflammation process (Pertosa 
et al. 2005). To the best of our knowledge, there have been 
no studies published in the searched databases reporting 
the relationship between L-carnitine and frailty. Even 
our study failed to provide evidence for the relationship 
between the L-carnitine and acyle carnitine with frailty. 
The non-significant results in our study may be due to the 
small sample size, majority of the participants been well 
nourished as micronutrients deficiency affects the ability 
of the body to synthesize L-carnitine. There is a need for 
further research to examine this relationship by including 
all the susceptible mechanisms that may involve in frailty 
such as CPTII enzyme and OCTN2 mutation or functional 
decline. 
CONCLUSION
Frailty was associated with hyper inflammatory status as 
indicated by the significant higher level of serum IL-6 and 
TNF-α). Vitamin D deficiency increased the risk of frailty by 
three times. Chronic disease management, healthy lifestyle 
TABLE 4. Frailty predictors from selected biomarkers
Factors B P value Exp (B) Exp (B) P 
Age 0.13 0.012* 1.12 2.63 0.000**
Gender 0.167 0.764 1.12
Vitamin D <25
(ng/mL)
1.25 0.034* 3.69
TNF α 
(pg/mL)
0.13 0.058 1.1
IGF-1
(ng/mL)
-0.09 0.07 0.9
IL-6
(pg/mL)
0.127 0.02 1.2
Cox & Snell R square = 0.157 and Nagelkerke R square = 0.2.91
Abbreviations: IL-6: interleukin 6, TNF-α: tumor necrosis factor – alpha, IGF-1: Insulin like growth factor.
** Significant at p<0.01 using Binary logistic regression test
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behavior and diet are important to improve vitamin D 
status and inflammatory markers in order to prevent frailty 
among older adults. 
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